top of page
< Back

Levomilnacipran


Mechanism of action:

Levomilnacipran is a serotonin-norepinephrine reuptake inhibitor and is the active enantiomer of milnacipran. Levomilnacipran primarily binds to and inhibits the norepinephrine transporter, with greater affinity than for the serotonin transporter, thereby increasing norepinephrine concentration in the synaptic cleft and enhancing norepinephrine-mediated central nervous system signaling. It also secondarily binds to the serotonin transporter, increasing serotonin (5-HT) concentration in the synaptic cleft and helping regulate mood and anxiety-related symptoms.

Reference(s):

1. Asnis GM et al. (2015). Levomilnacipran for the treatment of major depressive disorder: a review. Neuropsychiatr Dis Treat. 


2. Mago R et al. (2014). Levomilnacipran: a newly approved drug for treatment of major depressive disorder. Expert Rev Clin Pharmacol. 


3. Bruno A et al. (2016). The Role of Levomilnacipran in the Management of Major Depressive Disorder: A Comprehensive Review. Curr Neuropharmacol.

bottom of page